• FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

  • Jun 21 2024
  • Length: 57 mins
  • Podcast

FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

Listen for free

View show details

  • Summary

  • Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

    Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

    In this episode, we discuss:

    • The FDA advisory committee process and its implications for drug approvals
    • Functional unblinding and expectancy effects in psychedelic clinical trials
    • Potential impacts on the broader psychedelic medicine industry
    • The future of psychedelic-assisted psychotherapy protocols
    • Neuroplastogen development and non-hallucinogenic approaches
    • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

    Credits:

    Created by Greg Kubin and Matias Serebrinsky
    Host: Matias Serebrinsky & Greg Kubin
    Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

    Find us at businesstrip.fm and psymed.ventures
    Follow us on Instagram and Twitter!
    Theme music by Dorian Love
    Additional Music: Distant Daze by Zack Frank
    Show more Show less
Show more Show less

What listeners say about FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available